Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin

Archives of Gynecology and Obstetrics

Volumn 289, Issue 4, 2014, Pages 859-864

  Furukawa, Naoto ^a   Akasaka, Juria ^a   Shigemitsu, Aiko ^a   Sasaki, Yoshikazu ^a   Nagai, Akira ^a   Kawaguchi, Ryuji ^a   Kobayashi, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Carboplatin; Chemotherapy induced nausea and vomiting; Gynecologic malignancy; Paclitaxel

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; GRANISETRON; PACLITAXEL; SEROTONIN ANTAGONIST;

ADULT; AGED; ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GYNECOLOGIC CANCER; HUMAN; HYPEREMESIS GRAVIDARUM; HYPERTENSION; MAJOR CLINICAL STUDY; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DEXAMETHASONE; FEMALE; GENITAL NEOPLASMS, FEMALE; GRANISETRON; HUMANS; HYPEREMESIS GRAVIDARUM; HYPERTENSION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAUSEA; PACLITAXEL; PREGNANCY; QUESTIONNAIRES; RETROSPECTIVE STUDIES; VOMITING;

EID: 84899428557     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-3058-7     Document Type: Article

References (23)

1. Ushijima K (2009) Current status of gynecologic cancer in Japan. J Gynecol Oncol 20(2):67-71. doi:10.3802/jgo.2009.20.2.67
2. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH (1983) On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19(2):203-208 (Pubitemid 13155858)
3. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7(2):189-195 (Pubitemid 26094884)
4. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95(1):155-163. doi:10.1002/cncr.10630 (Pubitemid 34743494)
5. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. doi:10.1200/JCO.2010.34.4614
6. Gralla RJ, Roila F, Tonato M, Herstedt J (2011) MASCC Antiemetic Guidelines. http://www.mascc.org/antiemetic-guidelines. Accessed 5 Oct 2012
7. NCCN Clinical Practice Guideline in Oncology (2012) Antiemesis. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site. Accessed 5 Oct 2012
8. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade- Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8):viii7-viii12. doi:10.1093/annonc/mdi961
9. Miller D, Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, Tewari K, DiSilvestro P, Pearl M, Zaino R (2012) Late-Breaking Abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125(3):771. doi:10.1016/j.ygyno.2012.03.034
10. Kitagawa R, Katsumata N, Shibata T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H, Kamura T (2012) A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505). J Clin Oncol 30(15-suppl):5006
11. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320-1329
12. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB (2004) Phase III randomized trial of docetaxel- carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96(22):1682-1691 (Pubitemid 39585637)
13. Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423-431. doi:10.1007/s00520-009-0680-9
14. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570-1577 (Pubitemid 37304615)
15. Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18(9):1171-1177. doi:10.1007/s00520-009-0737-9
16. Warr DG, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer. doi:10.1007/s00520-010-0899-5
17. Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64(5):1117-1122 (Pubitemid 19208867)
18. Hesketh PJ, Aapro M, Street JC, Carides AD (2009) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. doi:10.1007/s00520-009-0737-9
19. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24(27): 4472-4478. doi:10.1200/JCO.2006.05.6382 (Pubitemid 46630986)
20. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331-1338
21. Siddiqui MA, Scott LJ (2004) Palonosetron. Drugs 64(10): 1125-1132 (discussion 1133-1124)
22. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011-1015. doi:10.1038/sj.bjc.6603048
23. Aapro M, Fabi A, Nole F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21(5):1083-1088. doi:10.1093/annonc/mdp584